One Iowa doctor’s relentless pursuit turned cystic fibrosis from a child’s death sentence into a life reclaimed through breath-giving science.
Story Highlights
- Dr. Michael Welsh’s 1970s encounter with a dying CF patient ignited decades of research cloning the CFTR gene.
- Breakthrough drugs like Trikafta, rooted in Welsh’s work, now help 90% of CF patients breathe normally.
- Poet William O’Neal II, once near death, met Welsh in an Iowa City bar, embodying the human triumph.
- Life expectancy for CF patients doubled to over 50 years, slashing hospitalizations by 60-70%.
Dr. Welsh’s Pivotal Patient Encounter
During medical school at University of Iowa Carver College of Medicine in the 1970s, Dr. Michael Welsh watched a young cystic fibrosis patient gasp for air. She died soon after. That moment redirected his career from general medicine to pulmonary research targeting CF’s root cause: defective CFTR gene mutations clogging lungs with mucus. Welsh committed to fixing the ion channel failure. His determination launched a scientific revolution. Patients like her would soon breathe freely.
Genetic Breakthrough and Drug Development
Welsh’s lab cloned the CFTR gene in 1989 alongside Lap-Chee Tsui and Francis Collins. This discovery enabled targeted therapies. He co-founded Vertex Pharmaceuticals’ CF program. Ivacaftor, approved in 2012 as Kalydeco, treated 4-5% of patients. Orkambi followed in 2015, Symdeko in 2018. Trikafta launched in 2019, addressing 90% of mutations. Welsh’s foundational science powered these modulators, transforming CF management.
Patient Transformation Through Trikafta
William O’Neal II, a poet from Iowa Writers’ Workshop, nearly succumbed to CF before Trikafta. The drug restored his lung function, allowing normal breathing and creative pursuits like grandparenting. His family once prayed for miracles; Welsh delivered one via pills. O’Neal’s story underscores how modulators normalize nutrition, fertility, and daily life. Over 90% of 40,000 U.S. CF patients now benefit, cutting therapies and hospitalizations.
A chance bar meeting in Iowa City united Welsh and O’Neal. The doctor recognized his former patient. Their encounter symbolized science’s personal reach, blending research rigor with human resilience rooted in Midwestern grit.
Stakeholders Driving CF Progress
University of Iowa hosted Welsh’s lab, gaining prestige. Cystic Fibrosis Foundation invested over $20 million in Vertex, pioneering venture philanthropy. Vertex generates billions from CF drugs, with Welsh advising scientifically. Patients and families exert grassroots pressure for access. This alliance—academia, philanthropy, pharma—accelerated FDA approvals, aligning innovation with real needs.
The Man Who Gives Breath Back to His Patients https://t.co/aWJb8YRmB1 pic.twitter.com/QSQCaCTkqs
— Healthy Hoss 🍎 (@HealthyHoss) May 6, 2026
Ongoing Advances and Lasting Legacy
Vertex approved vanzacaftor in 2024 for once-daily dosing. Welsh, in his 70s, researches rare mutations at Iowa. Trials target infants and broader fixes, including mRNA therapies by 2025. Global impacts reach 100,000 patients. CF sets precision medicine precedents, from funding models to orphan drugs. Welsh’s work proves persistent science delivers freedom.
Sources:
Vertex: Cystic Fibrosis Science
